Partners have paid about 2.8% of disclosed headline value
$M. Headline covers Takeda, AbbVie and Lundbeck; RevMed and Bayer are undisclosed.
Partners have paid about 2.8% of disclosed headline value
$M. Headline covers Takeda, AbbVie and Lundbeck; RevMed and Bayer are undisclosed.
